Literature DB >> 19774404

Expenditures of the German statutory health insurance system for patients suffering from acute coronary syndrome and treated with percutaneous coronary intervention.

Heiko Friedel1, Anne Delges, Johannes Clouth, Dana T Trautvetter.   

Abstract

Patients with acute coronary syndrome (ACS) are in need of cost-intensive treatment involving different aspects of the German Health System. Percutaneous coronary intervention (PCI) is the treatment of choice for a large proportion of cases. In the present study, an analysis of the cost impact of ACS with focus on PCI therapy was conducted across-the-board for the German Health System. Results indicated that 85% of all costs arising from treatment of ACS with a trial of PCI are due to in-patient care. Projection of results onto the entire insurant collective of the statutory health system estimated a total of Euro 954,995,603-a proportional 0.7% of all expenditure by statutory health insurance in 2005.

Entities:  

Mesh:

Year:  2009        PMID: 19774404     DOI: 10.1007/s10198-009-0181-2

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  16 in total

1.  [Guidelines: acute coronary syndrome (ACS). 1: ACS without persistent ST segment elevations].

Authors:  C W Hamm
Journal:  Z Kardiol       Date:  2004-01

2.  Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.

Authors:  Jean-Pierre Bassand; Christian W Hamm; Diego Ardissino; Eric Boersma; Andrzej Budaj; Francisco Fernández-Avilés; Keith A A Fox; David Hasdai; E Magnus Ohman; Lars Wallentin; William Wijns
Journal:  Eur Heart J       Date:  2007-06-14       Impact factor: 29.983

3.  The impact of acute coronary syndrome on clinical, economic, and cardiac-specific health status after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: 1-year results from the stent or surgery (SoS) trial.

Authors:  Zefeng Zhang; John A Spertus; Elizabeth M Mahoney; Jean Booth; Fiona Nugara; Rodney H Stables; William S Weintraub
Journal:  Am Heart J       Date:  2005-07       Impact factor: 4.749

Review 4.  [Acute coronary syndrome with and without ST elevation].

Authors:  Helge Möllmann; Albrecht Elsässer; Holger M Nef; Michael Weber; Christian W Hamm
Journal:  Herz       Date:  2006-12       Impact factor: 1.443

5.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

6.  Acute coronary syndromes in Europe: 1-year costs and outcomes.

Authors:  Matthew J Taylor; Paul A Scuffham; Patrick L McCollam; David E Newby
Journal:  Curr Med Res Opin       Date:  2007-03       Impact factor: 2.580

7.  Total first-year costs of acute coronary syndrome in a managed care setting.

Authors:  Lida R Etemad; Patrick L McCollam
Journal:  J Manag Care Pharm       Date:  2005-05

8.  Costs of an early intervention versus a conservative strategy in acute coronary syndrome.

Authors:  David M Epstein; Mark J Sculpher; Tim C Clayton; Rob A Henderson; Stuart J Pocock; Martin J Buxton; Keith A A Fox
Journal:  Int J Cardiol       Date:  2007-08-16       Impact factor: 4.164

9.  Cost-effectiveness of early versus selectively invasive strategy in patients with acute coronary syndromes without ST-segment elevation.

Authors:  L M Dijksman; A Hirsch; F Windhausen; F F Asselman; J G P Tijssen; M G W Dijkgraaf; R J de Winter
Journal:  Int J Cardiol       Date:  2008-01-15       Impact factor: 4.164

10.  Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.

Authors:  Sigmund Silber; Per Albertsson; Francisco F Avilés; Paolo G Camici; Antonio Colombo; Christian Hamm; Erik Jørgensen; Jean Marco; Jan-Erik Nordrehaug; Witold Ruzyllo; Philip Urban; Gregg W Stone; William Wijns
Journal:  Eur Heart J       Date:  2005-03-15       Impact factor: 29.983

View more
  4 in total

1.  Treatment costs of acute myocardial infarction in the Netherlands.

Authors:  R R Soekhlal; L T Burgers; W K Redekop; S S Tan
Journal:  Neth Heart J       Date:  2013-05       Impact factor: 2.380

2.  Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model.

Authors:  Husam Abdel-Qadir; Idan Roifman; Harindra C Wijeysundera
Journal:  CMAJ Open       Date:  2015-12-09

Review 3.  Patient-level costs of major cardiovascular conditions: a review of the international literature.

Authors:  Gina Nicholson; Shravanthi R Gandra; Ronald J Halbert; Akshara Richhariya; Robert J Nordyke
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-21

4.  The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization.

Authors:  Andreas Schwarting; Heiko Friedel; Elena Garal-Pantaler; Marc Pignot; Xia Wang; Henk Nab; Barnabas Desta; Edward R Hammond
Journal:  Rheumatol Ther       Date:  2021-02-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.